Session 9 - CROI 2009

Session 9 Oral Abstracts
Pharmacogenetics, Pharmacoenhancement, and Complications of ART
Monday, 10 am-12 noon
Room: Room 710

10:00 am 37	Predictors of Kidney Tubulopathy in HIV Patients Treated with Tenofovir: A Pharmacogenetic Study Sonia Rodriguez Novoa*¹, P Labarga¹, V Soriano¹, D Egan², J Morello¹, G González-Pardo¹, L Cuenca¹, S Khoo², D Back², and A Owen² ¹Hosp Carlos III, Madrid, Spain and ²Univ of Liverpool, UK
10:15 am 38	HIV-infected Persons Continue to Lose Kidney Function despite Successful ART Andy Choi*, M Shlipak, P Hunt, J Martin, and S Deeks Univ of California, San Francisco, US
10:30 am 39	Absorption, Distribution, Metabolism, and Excretion Pathway Pharmacogenetics of Lopinavir Rubin Lubomirov*¹, C Csajka¹, S Colombo¹, R Martinez¹, P Descombes², L Decosterd¹, and A Telenti¹ ¹Univ Hosp Ctr and Univ of Lausanne, Switzerland and ²NCCR Frontiers in Genetics, Univ of Geneva, Switzerland
10:45 am 40	GS-9350: A Pharmaco-enhancer without Anti-HIV Activity A Mathias, M Lee, C Callebaut, L Xu, L Tsai, B Murray, H Liu, K Yale, D Warren, and Brian Kearney* Gilead Sci, Foster City, CA, US
11:00 am 41	Preclinical and Early Clinical Evaluation of SPI-452, a New Pharmacokinetic Enhancer S Gulnik, M Eissenstat, E Afonina, D Ludtke, J Erickson, R Dagger, B Wynne, and Robert Guttendorf* Sequoia Pharmaceuticals, Gaithersburg, MD, US
11:15 am 42LB	Rosiglitazone Improves Lipoatrophy in Patients Receiving Thymidine-sparing Regimens D El Bejjani^1,2, M Tungsiripat³, N Rizk², M O'Riordan^2,4, A Ross^2,4, C Hileman^2,4, N Storer^2,4, D Harrill^2,4, and Grace McComsey*^2,4 ¹Metrohealth Med Ctr, Cleveland, OH, US; ²Case Western Reserve Univ, Cleveland, OH, US; ³Cleveland Clinic Fndn, OH, US; and ⁴Univ Hosps of Cleveland, OH, US
11:30 am 43LB	Impact of Specific NRTI and PI Exposure on the Risk of Myocardial Infarction: A Case-Control Study Nested within FHDH ANRS CO4 S Lang¹, M Mary-Krause¹, L Cotte², J Gilquin³, M Partisani⁴, A Simon⁵, F Boccara⁶, Dominique Costagliola*¹, and the Clinical Epi Group of the French Hosp Database on HIV ¹INSERM U943, Univ of Pierre and Marie Curie, Paris, France; ²Hosp Hotel Dieu, Lyon, France; ³Hosp St-Joseph, Paris, France; ⁴CHRU Strasbourg, France; ⁵Hosp Pitie-Salpetriere, Paris, France; and ⁶Hosp St Antoine, Paris, France
11:45 am 44LB	Risk of Myocardial Infarction with Exposure to Specific ARV from the PI, NNRTI, and NRTI Drug Classes: The D:A:D Study Jens Lundgren*¹, P Reiss², S Worm¹, R Weber³, W El-Sadr⁴, S De Wit⁵, M Law⁶, A d’Arminio Monforte⁷, C Pradier⁸, C Sabin⁹, and Aquataine, AHOD, ATHENA, INSIGHT, EuroSIDA, ICONA, Nice, SHCS, St Pierre Cohorts & D:A:D Study Group ¹Rigshospitalet, Univ of Copenhagen, Denmark; ²Academic Med Ctr, Amsterdam, The Netherlands; ³Univ Hosp Zurich, Switzerland; ⁴Columbia Univ, New York, NY, US; ⁵St Pierre Hosp, Brussels, Belgium; ⁶Univ of New South Wales, Sydney, Australia; ⁷Univ of Milan, Italy; ⁸L`Archet Hosp, Nice, France; and ⁹Royal Free and Univ Coll Med Sch, London, UK